Inhibikase Therapeutics Inc. (IKT)
NASDAQ · Healthcare
Inhibikase Therapeutics Inc. EPS 2020–2024
Inhibikase Therapeutics Inc. annual/quarterly eps history and growth rate from 2021 to 2026. Earnings per share (EPS) is a company's net profit divided by the number of diluted shares outstanding. Higher EPS generally indicates greater profitability.
- Inhibikase Therapeutics Inc. eps for the quarter ending March 31, 2026 was $0.10, a 33.33% decrease year-over-year.
- Inhibikase Therapeutics Inc. annual eps for 2024 was $1.16, a 63.29% decrease from 2023.
- Inhibikase Therapeutics Inc. annual eps for 2023 was $3.16, a 26.17% decrease from 2022.
- Inhibikase Therapeutics Inc. annual eps for 2022 was $4.28, a 428.40% increase from 2021.
- Inhibikase Therapeutics Inc. annual eps for 2021 was $0.81.
EPS
ANNUAL · USD
QUARTERLY · USD
YEAR-OVER-YEAR GROWTH · %
Inhibikase Therapeutics Inc. EPS — FAQ
Inhibikase Therapeutics Inc. (IKT) eps over the last 5 years — annual and quarterly figures with year-over-year growth and charts.
What is Inhibikase Therapeutics Inc.'s eps?
Inhibikase Therapeutics Inc. (IKT) reported eps of $-1.16 for fiscal 2024.
Where can I see IKT's eps history?
The chart and table above show Inhibikase Therapeutics Inc.'s eps by year and by quarter, including the growth rate.